Canaloplasty and Trabeculotomy Results in Glaucoma Patients

Studies assessed data registry outcomes using two different devices.

Sarah Atta, MD; Baraa Nawash, MD; Samantha Goldburg, MD; and Mary Qiu, MD

Glaucoma Today

Key Takeaways A prospective, real-world, multicenter study found that ab interno canaloplasty, whether performed alone or in combination with phacoemulsification, had favorable safety and efficacy profiles. A retrospective cohort study found that standalone ab interno canaloplasty and trabeculotomy provided clinically and statistically significant IOP reductions that were sustained through 36 months in patients with primary open-angle glaucoma. A Prospective, Real-World, Multicenter Study to Support the Role of Ab-Interno Canaloplasty in Glaucoma Management Kerr N, Lubeck D, Barton K, et al1 Industry support for this study: Several study authors disclosed consulting relationships with Nova Eye Medical ABSTRACT SUMMARY This prospective, real-world, multicenter study drew on the iTrack Global Data Registry to evaluate ab interno canaloplasty (ABiC) outcomes in 254 patients (344 eyes) with ocular hypertension or open-angle glaucoma (primary or secondary, all severities) over a mean follow-up period of 20.5 months. The study assessed ABiC combined with phacoemulsification and ABiC alone. For combined cases (n = 313 eyes), at the last follow-up visit, the mean IOP had decreased from 17.2 to 14.1 mm Hg, and the mean number of medications had decreased from 2.1 to 1.3 (P < .001). Success was defined using 2024 AAO criteria2 as either a reduction in medication usage of at least one agent without an increase in IOP or at least a 20% decrease in IOP to a level of 21 mm Hg or less without an increase in the number of medications, additional procedures, a loss of light perception, or hypotony. Overall, 61.9% of eyes in the combined group achieved success, and 43% became medication-free (vs 7% preoperatively). For standalone ABiC (n = 24 eyes), mean IOP decreased from 20.2 to 15.3 mm Hg, and the mean number of medications was reduced from 2.3 to 1.5 (P < .01). Success was achieved in 35% of eyes, and 46% became medication-free. IOP and medication reductions were significant across all disease subtypes and severities.

Personalizing Myopia Management

Consider these nonvisual factors when determining which intervention to prescribe to children.

Cynthia Noorani, OD, MPH, FAAO

Modern Optometry

The Biggest Financial Decision: Selling a Practice

The sale price gets all the attention. How much wealth you keep depends on something else entirely: whether the experts around you are working from the same playbook.

David Mandell, JD, MBA

Retina Today

Key Takeaways The sale of a retina practice changes how a physician earns income, pays taxes, invests assets, and plans for retirement. When selling a practice, a coordinated plan brings together the owner’s certified public accountant, wealth advisor, attorney, banker, and broker to ensure each decision reinforces the overall plan. A successful practice sale ensures that years of work translate into lasting financial flexibility and peace of mind. When a retina specialist sells a practice, the instinct is to fixate on one number: the sale price. That’s understandable, as it represents decades of clinical excellence, business ownership, and personal sacrifice. But the price is only part of the financial outcome. The larger question is: After the transaction closes, how much of those proceeds become lasting wealth? The answer depends on the planning that takes place well before a buyer ever appears. Most successful physician-owners have a capable team: a certified public accountant (CPA) who prepares the tax return, a wealth advisor who manages investments, an attorney who handles contracts, a banker, and—once a sale is on the horizon—a broker or investment banker running the transaction. Each brings valuable expertise.